BHV-8000

BHV-8000 is a novel, orally bioavailable, brain-penetrant small molecule that acts as a highly selective dual inhibitor of tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1), key enzymes in the JAK/STAT signaling pathway. It is designed to avoid the safety liabilities associated with JAK2 and JAK3 inhibition. By targeting TYK2 and JAK1, BHV-8000 modulates neuroinflammatory responses implicated in the progression of neurodegenerative diseases. The drug has demonstrated robust central nervous system penetration and target engagement in clinical studies, with reductions observed in inflammatory biomarkers such as IP-10, hsCRP, and IFN-gamma. Preclinical models show that it improves motor function and reduces microglial activation while promoting neuronal survival. Developed by Biohaven Pharmaceuticals (originator: Hangzhou Highlightll Pharmaceutical), it is being investigated primarily for early Parkinson’s disease but also for Alzheimer’s disease, multiple sclerosis, other CNS disorders, and prevention of amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapies[1][2][5][6].

Other names

BHV 8000BHV8000BHV-8000TLL041TLL-041TLL 041